econazole

(redirected from Pevaryl)

econazole

[ĕ-kon´ah-zōl]

an imidazole derivative used as the nitrate salt as a broad-spectrum antifungal agent, applied topically in the treatment of cutaneous candidiasis and various forms of tinea.

econazole

(ĭ-kŏn′ə-zōl′)

A broad-spectrum antifungal agent used in the treatment of athlete's foot and related fungal infections.

econazole

A broad-spectrum antifungal drug used in local (topical) application. Brand names are Ecostatin, Pevaryl, Pevaryl TC and Gyno-Pevaryl.

antifungal agent

Any substance which destroys or prevents the growth of fungi. It is one of the antibiotic groups. There are several classes of antifungal drugs: Polyenes, which cause an increase in fungal cell wall permeability leading to its death. Examples: amphotericin B, natamycin, nystatin. Azoles, which act either by inhibiting the synthesis of ergosterol, a component of fungal cell wall or by causing direct wall damage. Examples: clotrimazole, econazole, fluconazole, itraconazole, ketoconazole, miconazole. Pyrimidines, which interfere with the normal function of fungal cells. Example: flucytosine. Syn antimycotic agent.

Mentioned in ?

References in periodicals archive ?

It has around 90 employees and its product portfolio includes brands such as Flux, Nailner and Pevaryl.

United States : White & Case Advises Karo Pharma on Acquisition of Trimb

Other key brands include the leading antipruritics brand Foille by Sanofi-Aventis, Pevaryl by Janssen-Cilag, which is present in both topical antifungals and vaginal antifungals, and Proctolyn by Recordati, which is the top ranking brand in haemorrhoid treatments.

Dermatologicals in Italy - New Study Released

The leader was followed by Janssen-Cilag AG, which was present with three major brands: Pevaryl (topical antifungals and medicated shampoos), Daktarin (topical antifungals) and Regaine (hair loss treatments).

Just Published: "Dermatologicals in Switzerland"

Further divestitures: In Italy, the combination of J&J's antifungal creams, Daktarin, Pevaryl and Nizoral, and PCH's Trosyd, would bring the number of producers down from three to two.